Leap Therapeutics Inc (NASDAQ:LPTX) has received a consensus broker rating score of 1.50 (Buy) from the two brokers that cover the stock, Zacks Investment Research reports. One analyst has rated the stock with a buy rating and one has assigned a strong buy rating to the company.
Brokers have set a 1-year consensus target price of $15.50 for the company and are forecasting that the company will post ($0.51) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Leap Therapeutics an industry rank of 195 out of 265 based on the ratings given to related companies.
Separately, Zacks Investment Research raised Leap Therapeutics from a “hold” rating to a “buy” rating and set a $7.00 price objective for the company in a report on Tuesday, January 9th.
An institutional investor recently bought a new position in Leap Therapeutics stock. Sabby Management LLC bought a new stake in shares of Leap Therapeutics Inc (NASDAQ:LPTX) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 89,350 shares of the company’s stock, valued at approximately $558,000. Sabby Management LLC owned about 0.72% of Leap Therapeutics at the end of the most recent quarter. Institutional investors own 3.25% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “Brokerages Expect Leap Therapeutics Inc (LPTX) to Post ($0.51) EPS” was originally published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The legal version of this article can be read at https://sportsperspectives.com/2018/03/11/brokerages-expect-leap-therapeutics-inc-lptx-to-post-0-51-eps.html.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, formerly HealthCare Pharmaceuticals, Inc, is a clinical-stage biopharmaceutical company. The Company engages in acquiring and developing therapeutics in cancer biology. Its lead product candidates for use in clinical trials include TRX518 and DKN-01. DKN-01 is a monoclonal antibody targeting Dickkopf-related protein 1 (DKK1).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.